Abstract: As a new category of oral hypoglycemic agents, sodiumglucose cotransporter 2 inhibitors (SGLT2i) can decrease hyperglycaemia by blocking glucose reabsorption in proximal tubule and promoting urinary glucose excretion. Besides, it has been found to have cardiovascular and kidney protective effects in addition to glycemic control function. Studies have shown that SGLT2i is beneficial to the longterm survival of kidney transplant recipients (KTRs) by the means of inducing hypoxia inducible factor and reduce ischemia reperfusion injury, reducing cyclosporininduced glomerular and tubulointerstitial fibrosis and renal inflammation, and lower blood pressure which may be associated with natriuresis, osmotic diuresis, decreased uric acid, improved endothelial function and inhibited sympathetic nervous system. This review aim to clarify the efficacy and safety of SGLT2i for KTRs with diabetes mellitus.

Key words: kidney transplantation, diabetic nephropathy, post-transplant diabetes mellitus, sodium-glucose cotransporter 2 inhibitors